Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06063317 · ClinicalTrials.gov registry record · Phase 1
A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)
A Phase 1 study, sponsored by Imugene Limited.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT06063317: Clinical Trial Phase 1 study, sponsored by Imugene Limited.
NCT06063317 is a Phase 1 study that was terminated before completion, run by Imugene Limited. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06063317, a Phase 1 study, was terminated before completion, sponsored by Imugene Limited.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is an open-label, dose escalation and dose expansion, multi-center phase I study evaluating the safety and tolerability of CF33-CD19 administered intravenously (IV) or intratumorally (IT) in combination with blinatumomab and with or without hydroxyurea in adults with advanced or metastatic solid tumors.
Primary Outcome
Adverse events will be graded according to CTCAE v5.0.
Interventions
- DRUG Blinatumomab
- BIOLOGICAL CF33-CD19 IT Monotherapy
- BIOLOGICAL CF33-CD19 IV Monotherapy
- BIOLOGICAL CF33-CD19 IT Combination
- BIOLOGICAL CF33-CD19 IV Combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-10-02 |
| Est. Completion | 2026-02-02 |
| Phase | Phase 1 |
Why NCT06063317 stopped before completion
NCT06063317 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 5 interventions - of which Blinatumomab is the first listed.
NCT06063317 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06063317 about?
NCT06063317 is a clinical study titled "A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)". This is an open-label, dose escalation and dose expansion, multi-center phase I study evaluating the safety and tolerability of CF33-CD19 administered intravenously (IV) or intratumorally (IT) in combination with blinatumomab and with or without hydroxyurea in adults with advanced or metastatic soli...
What is the current status of trial NCT06063317?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2023-10-02. Estimated completion is 2026-02-02.
What interventions are being tested in trial NCT06063317?
The interventions under investigation include: Blinatumomab (DRUG), CF33-CD19 IT Monotherapy (BIOLOGICAL), CF33-CD19 IV Monotherapy (BIOLOGICAL), CF33-CD19 IT Combination (BIOLOGICAL), CF33-CD19 IV Combination (BIOLOGICAL).
Who is sponsoring clinical trial NCT06063317?
This trial is sponsored by Imugene Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06063317's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI